Aurinia Pharmaceuticals Stock (NASDAQ: AUPH)

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Geographically, it derives maximum revenue from the United States.

bz_pharma_briefs

Biotech

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

AUPH

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

COTY

CRSP

GKOS

JACK

ROOT

UCTT

WING

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Penny Stocks

Intraday Update

AMWL

APPN

CETY

CGNX

CHNR

CNVS

DNOW

DTSS

DWAC

ELWS

EPAM

EXPR

FROG

FSLY

IFBD

INFA

INOD

JXJT

LYFT

MANU

NNOX

NSIT

ORGS

PEGA

PENN

PLCE

PTEN

RNLX

ROMA

RVSN

SABR

SHAK

SLVM

SOUN

SPWR

TELO

TWLO

UDMY

ULBI

UPXI

ZBRA

Shares of  Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals Inc

Press Releases

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Axonis Therapeutics Announces $115 Million Series A Financing

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Comments

Aurinia Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga